ARTICLE | Finance
Royalty’s $1.7B IPO latest sign of a biopharma market on a roll
Four companies set terms for NASDAQ IPOs: Repare, Forma, Progenity and Genetron
June 17, 2020 3:16 AM UTC
Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s offering also earned it the largest postmoney valuation to date this year.
The IPO comes as four other companies in the queue moved closer to their debuts: Repare Therapeutics Inc., Forma Therapeutics Inc., Progenity Inc. and Genetron Holdings Ltd. set terms for their offerings Monday...